Theratechnologiesの企業価値
Theratechnologiesの企業価値は何ですか。
Theratechnologies, Inc.の企業価値は125.30M$です。
企業価値の定義は何ですか。
企業価値は、企業の総市場価値の尺度です。これは、負債、少数株主持分および優先株式から現金および現金同等物を差し引いた時価総額として計算されます。
It is a sum of claims by all claimants including creditors (secured and unsecured) and shareholders (preferred and common). Enterprise value is one of the fundamental metrics used in business valuation, financial modeling, accounting, portfolio analysis, and risk analysis. Enterprise value is more comprehensive than market capitalization, which only reflects common equity and is considered more representative of a company’s value. Enterprise value reflects the opportunistic nature of business and may change substantially over time because of both external and internal conditions.
Enterprise value can be negative if the company holds abnormally high amounts of cash that is not reflected in the market value of the stock and total capitalization. Cash is subtracted in the calculation because it reduces the net cost to a potential purchaser. The effect applies whether the cash is used to issue dividends or to pay down debt. Value of minority interest is added because it reflects the claim on assets consolidated into the firm in question. Value of associate companies is subtracted because it reflects the claim on assets consolidated into other firms. EV should also include such special components as unfunded pension liabilities, employee stock options, environmental provisions, abandonment provisions, and so on, since they also reflect claims on the company.
TSXのセクタHealth Careにおける企業価値の企業と比べるTheratechnologies
Theratechnologiesは何をしますか。
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH-1902 for the treatment of triple negative breast cancer; and TH-1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.
Theratechnologiesと類似の企業価値
- Litigation Capital Managementの企業価値は125.07M$です。
- Freegold Venturesの企業価値は125.09M$です。
- Jericho Oilの企業価値は125.09M$です。
- Skylight Healthの企業価値は125.13M$です。
- Jinhuiの企業価値は125.20M$です。
- Anpario plcの企業価値は125.23M$です。
- Theratechnologiesの企業価値は125.30M$です。
- Lippo China Resourcesの企業価値は125.32M$です。
- Galena Miningの企業価値は125.37M$です。
- AFC plcの企業価値は125.43M$です。
- Georgia Healthcare Plcの企業価値は125.45M$です。
- Sportking Indiaの企業価値は125.72M$です。
- Manolete Partners Plcの企業価値は125.82M$です。